We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$742M
AUM Growth
-$165M
Cap. Flow
-$34.2M
Cap. Flow %
-4.61%
Top 10 Hldgs %
45.48%
Holding
92
New
8
Increased
13
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
KA
Kineta, Inc. Common Stock
KA
+$16.9M
2
BPMC
Blueprint Medicines
BPMC
+$16.4M
3
TBPH icon
Theravance Biopharma
TBPH
+$9.51M
4
NVRO
NEVRO CORP.
NVRO
+$9.42M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$7.84M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$23.4M
2
MGNX icon
MacroGenics
MGNX
+$21.2M
3
CLLS
Cellectis
CLLS
+$12M
4
ADXS
Advaxis Inc
ADXS
+$9.85M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRNE
26
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$9.35M 1.26%
1,909,000
-212,013
-10% -$1.27M
SGYP
27
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$9.13M 1.23%
+1,500,000
New +$7.84M
BOLD
28
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.21M 1.11%
449,660
– –
RARE icon
29
Ultragenyx Pharmaceutical
RARE
$1.27B
$7.79M 1.05%
110,842
– –
ZYNE
30
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$7.49M 1.01%
480,501
– –
CRIS icon
31
Curis
CRIS
$2.76M
$7.43M 1%
1,205
– –
COLL icon
32
Collegium Pharmaceutical
COLL
$727M
$7.09M 0.96%
455,515
– –
MTVA
33
MetaVia Inc
MTVA
$10.2M
$7.06M 0.95%
14
– –
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$834M
$6.83M 0.92%
286,870
+171,310
+148% +$4.91M
CFRX
35
DELISTED
ContraFect Corporation
CFRX
$6.72M 0.91%
4,804
+3
+0.1% +$5.3K
AGEN
36
Agenus
AGEN
$324M
$5.86M 0.79%
72,400
-8,005
-10% -$786K
PFNX
37
DELISTED
Pfenex Inc.
PFNX
$5.74M 0.77%
632,559
– –
CNCE
38
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.54M 0.75%
+538,422
New +$4.92M
DXCM icon
39
DexCom
DXCM
$32.9B
$5.37M 0.72%
360,000
-40,000
-10% -$709K
DERM
40
DELISTED
Dermira, Inc.
DERM
$5.22M 0.7%
172,083
– –
FWP
41
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.09M 0.69%
48,454
– –
SCTL
42
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.86M 0.66%
672,345
-73,856
-10% -$505K
INDP icon
43
Indaptus Therapeutics
INDP
$417M
$4.62M 0.62%
362
– –
IVTY
44
DELISTED
Invuity, Inc
IVTY
$4.41M 0.59%
767,466
– –
CTMX icon
45
CytomX Therapeutics
CTMX
$586M
$4.08M 0.55%
371,636
– –
VIRX
46
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.62M 0.49%
+28,571
New +$3.98M
AAAP
47
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$3.32M 0.45%
+124,220
New +$4.18M
ASND icon
48
Ascendis Pharma A/S
ASND
$16.2B
$3.28M 0.44%
162,254
+100,000
+161% +$2M
XLRN
49
DELISTED
Acceleron Pharma
XLRN
$3.25M 0.44%
127,451
– –
AGRX
50
DELISTED
Agile Therapeutics
AGRX
$3.21M 0.43%
282
– –
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Cormorant Asset Management held 92 positions worth $742M, down 18% from $907M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $34.2M in Q4 2016, closing 15 positions and reducing 17 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Synergy Pharmaceuticals, Inc Common Stock worth $9.13M.

  • Cormorant Asset Management's largest Q4 2016 buy was Synergy Pharmaceuticals, Inc Common Stock: 1,500,000 shares worth $9.13M.
  • Cormorant Asset Management added most to Kineta, Inc. Common Stock in Q4 2016, an estimated $16.9M increase.
  • Cormorant Asset Management's biggest Q4 2016 reduction was Omeros, cutting an estimated $7.35M.
  • Cormorant Asset Management fully exited Clovis Oncology, Inc. in Q4 2016, selling an estimated $23.4M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $742M portfolio in Q4 2016.
  • Cormorant Asset Management opened 8 new positions and closed 15 in Q4 2016.
  • Cormorant Asset Management's portfolio value fell 18% quarter-over-quarter to $742M.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.